102 completed, 71 terminated, 34 recruiting, 14 withdrawn. 78 Phase 2, 49 Phase 1, 46 Not applicable, 12 Early Phase 1, 4 Phase 3.
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pilot Study Evaluating Tumor Microenvironment Interaction in Solid Tumor Patients 68Ga-FAPI-46 - Solid Tumor Cancer, Solid Tumor Malignancy | Early Phase 1 | Withdrawn | Eben Rosenthal | 2027-01-01 | 2026-01-21 | |
| PhII Study of Toripalimab Followed by Definitive CRT & Adjuvant Toripalimab in Locally Advanced ESCC Toripalimab, Carboplatin + Paclitaxel - Esophageal Squamous Cell Carcinoma | Phase 2 | Not yet recruiting | Vanderbilt-Ingram Cancer Center | 20 | 2026-12-31 | 2026-09-23 |
| Study Evaluating the Safety and Feasibility of Panitumumab-IRDye800 and [18F]NOTA-ABY-030 for Targeted Dual-Modality Imaging (TDMI) in Head and Neck Squamous Cell Carcinoma Panitumumab-IRDye800, [18F]NOTA-ABY-030 - HNSCC,Larynx, Pharynx and Oral Cavity, Squamous Cell Carcinoma | Phase 1 | Recruiting | Vanderbilt-Ingram Cancer Center | 30 | 2026-10-01 | 2026-10-19 |
| Window Trial of Intratumoral (IT) Neoadjuvant Fluorescently Labelled Nivolumab (nivo800) in Head and Neck Squamous Cell Carcinoma (HNSCC) Nivolumab-IRDye800 - HNSCC, SCC - Squamous Cell Carcinoma | Early Phase 1 | Recruiting | Vanderbilt-Ingram Cancer Center | 18 | 2026-09-30 | 2026-10-19 |
| Intrathecal Cytarabine and Hydrocortisone for the Early Treatment of ICANS in Patients Undergoing CAR T Therapy for Non Hodgkin Lymphoma Therapeutic Hydrocortisone, Cytarabine, Dexamethasone - Non-hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma | Phase 2 | Recruiting | Vanderbilt-Ingram Cancer Center | 59 | 2026-09-25 | 2026-10-02 |
| Casdatifan for the Treatment of Refractory Metastatic Clear Cell Renal Cell Carcinoma casdatifan - Refractory Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma | Phase 1 | Recruiting | Vanderbilt-Ingram Cancer Center | 12 | 2026-09-21 | 2026-09-25 |
| Cemiplimab and Quad Shot Radiation for Cutaneous Squamous Cell Carcinoma in the Head and Neck Cemiplimab, Radiation Therapy - Cutaneous Squamous Cell Carcinoma | Early Phase 1 | Recruiting | Vanderbilt-Ingram Cancer Center | 25 | 2026-09-01 | 2026-10-13 |
| Nemtabrutinib With CAR T Therapy in Relapsed/Refractory Mantle Cell Lymphoma Nemtabrutinib, Brexucabtagene autoleucel ( other names: brexu-cel , Tecartus) - Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma | Phase 2 | Recruiting | Vanderbilt-Ingram Cancer Center | 25 | 2026-07-31 | 2026-08-17 |
| Safety and Feasibility of Nivolumab-IRDye800CW in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC) Nivo800, Nivolumab - Hnscc, Head and Neck | Phase 1 | Recruiting | Vanderbilt-Ingram Cancer Center | 40 | 2026-07-03 | 2026-10-16 |
| A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC) Fianlimab, Ipilimumab, Nivolumab - Advanced Renal Cell Carcinoma (aRCC), Metastatic Renal Cell Carcinoma ( mRCC) | Phase 2 | Recruiting | Brian Rini | 120 | 2026-04-29 | 2026-09-04 |
| Study Evaluating [18F]NOTA-ABY030 for Safety and Tolerability of Indeterminate Primary and/or Metastatic Disease in Head and Neck Squamous Cell Carcinoma Cetuximab (EGFR inhibitor), 18F-NOTA-ABY-030, Positron Emission Tomography (PET) - SCC - Squamous Cell Carcinoma, Radiotracer | Phase 1 | Recruiting | Vanderbilt-Ingram Cancer Center | 25 | 2026-04-24 | 2026-05-11 |
| Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy [68Ga]Ga-ABY-025 - Locally Advanced Cancer, Metastatic Cancer | Early Phase 1 | Recruiting | Vanderbilt-Ingram Cancer Center | 30 | 2026-04-16 | 2026-05-08 |
| Window Trial of Fluorescently Labeled Nivolumab-IRDye800 (Nivo800) in High Grade Glioma (HGG) Nivolumab, Nivolumab-IRDye800 - Brain Cancer, HGG | Early Phase 1 | Recruiting | Eben Rosenthal | 38 | 2026-03-27 | 2026-07-01 |
| High-Resolution PET-CT Imaging for Surgical Margin Visualization Intra-op PET/CT Specimen Scanner - Cancer, Solid Malignant Tumors | Not applicable | Recruiting | Vanderbilt-Ingram Cancer Center | 50 | 2025-09-03 | 2026-05-08 |
| Window Trial of Fluorescently Labeled Panitumumab (Panitumumab-IRDye800) in Head and Neck Cancer Panitumumab IRDye 800 - HNSCC, HNSCC,Larynx, Pharynx and Oral Cavity | Phase 1 | Recruiting | Vanderbilt-Ingram Cancer Center | 70 | 2025-04-17 | 2026-08-03 |
| Biomarker Platform (Virtual Nodule Clinic) for the Management of Indeterminate Pulmonary Nodules Computed Tomography, Diagnostic Procedure, Best Practice - Lung Neoplasm | Not applicable | Active not recruiting | Vanderbilt-Ingram Cancer Center | 400 | 2024-10-31 | 2026-03-27 |
| Cryodevitalization for the Treatment of Early Stage Lung Cancer, CRYSTAL Trial Cryosurgery, Robotic Bronchoscopy, Bronchoscopy with Biopsy - Stage I Lung Cancer, Stage II Lung Cancer | Not applicable | Active not recruiting | Vanderbilt-Ingram Cancer Center | 13 | 2024-09-27 | 2026-08-18 |
| EBUS-TBNA vs Transbronchial Mediastinal Cryobiopsy for Adequacy of Next Generation Sequencing Endobronchial ultrasound with transbronchial needle aspiration, Bronchoscopy, Cryobiopsy - Lung Cancer | Phase 4 | Recruiting | Vanderbilt-Ingram Cancer Center | 250 | 2024-09-13 | 2026-02-02 |
| Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia Eltanexor, Venetoclax, Bone Marrow Aspiration and Biopsy - Relapsed Myelodysplastic Syndrome, Refractory Myelodysplastic Syndrome | Phase 1 | Recruiting | Vanderbilt-Ingram Cancer Center | 60 | 2024-08-14 | 2026-08-19 |
| Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers Endocrine Therapy, Biopsy of breast, Neratinib - Anatomic Stage I Breast Cancer, Anatomic Stage II Breast Cancer | Phase 2 | Recruiting | Vanderbilt-Ingram Cancer Center | 30 | 2024-06-11 | 2026-08-19 |
Showing 20 of 236. Sign in to see all of them.
Breast Neoplasms (43) · Lung Neoplasms (32) · Head and Neck Neoplasms (31) · Squamous Cell Carcinoma of Head and Neck (26) · Carcinoma, Non-Small-Cell Lung (25) · Neoplasms (18) · Lymphoma, Large B-Cell, Diffuse (14) · Lymphoma, Mantle-Cell (13) · Colorectal Neoplasms (11) · Leukemia, Lymphocytic, Chronic, B-Cell (11) · Lymphoma, B-Cell, Marginal Zone (11) · Lymphoma, Follicular (11) · Lymphoma, Non-Hodgkin (11) · Melanoma (11) · Burkitt Lymphoma (10)
Magnetic Resonance Spectroscopy (18) · Radiotherapy (13) · Blood Specimen Collection (12) · Immunohistochemistry (12) · Biopsy (11) · Erlotinib Hydrochloride (11) · Carboplatin (10) · Nivolumab (9) · Cisplatin (8) · Gene Expression Profiling (8) · Letrozole (8) · Paclitaxel (7) · Mass Spectrometry (6) · Celecoxib (5) · Docetaxel (5)
United States (210) · Canada (2) · United Kingdom (2) · Austria (1) · France (1) · Germany (1) · Honduras (1) · Japan (1) · Puerto Rico (1)
Barbara Murphy, MD (14) · A. Bapsi Chakravarthy, MD (12) · Ingrid Mayer, MD (10) · Barbara A. Murphy, MD (5) · Eben Rosenthal, MD (5) · Fabien Maldonado, MD (5) · Vicki Keedy, MD (5) · Eric Grogan, MD (4) · Ingrid Mayer, M.D. (4) · Jeffrey A. Sosman, MD (4) · Laura Goff, MD (4) · Madan Jagasia, MD (4) · Marta Crispens, MD (4) · Vandana Abramson, MD (4) · Evan Osmundson, MD, PhD (3)
PMID 25081901, PMID 40668552, PMID 17222711, PMID 18463792, PMID 18484593, PMID 19850643, PMID 22157574, PMID 23157877, PMID 23516312, PMID 23834234, PMID 24105358, PMID 25057165, PMID 25797743, PMID 25845992, PMID 26705063, PMID 26769865, PMID 28376728, PMID 30772283, PMID 30787124, PMID 31804281, PMID 32473681, PMID 32996842, PMID 33333150, PMID 33400907, PMID 33686901, PMID 33727260, PMID 33746047, PMID 33855995, PMID 33861486, PMID 34092233, PMID 34645413, PMID 34927159, PMID 35232410, PMID 35762890, PMID 35820740, PMID 36326731, PMID 37302348, PMID 37751186, PMID 37791898, PMID 37800415, PMID 37846664, PMID 37883803, PMID 37917111, PMID 38045245, PMID 38095878, PMID 38480701, PMID 38493482, PMID 39009301, PMID 39257031, PMID 39279435
P30CA068485 (77), P50CA090949 (6), P50CA098131 (2), R01CA212147 (2), R01CA252964 (2), 1UG3CA260318-01 (1), I01CX002686 (1), K12CA090625 (1), P50CA095103 (1), R01CA080195 (1), R01CA190612 (1), R01CA225005 (1), R01CA232516 (1), R01CA262287 (1), R01CA266233 (1)